Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases

Cancer research · Endometrial cancer

HER2‑ultralow expression was common in primary tumors, occurring in 49/117 EC cases (41.9%) and 11/52 HGSOC cases (21.2%).

HER2-directed antibody‑drug conjugates have expanded the clinical relevance of low‑level HER2 expression. However, the prevalence and clinical significance of HER2‑ultralow expression in gynecologic malignancies remain insufficiently defined. This study characterized the full spectrum of HER2 expression in endometrial carcinoma (EC) and high‑grade serous ovarian carcinoma (HGSOC), including matched metastatic lesions.

Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Original source

Related signals